PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pacira BioSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$36.34+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
Pacira BioSciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $190.49M | $177.38M | $196.87M | $178.04M | $180.35M | $167.59M | $187.25M | $167.72M | $176.39M | $165.82M | $179.76M | $163.58M | 99.0% | +5.6% |
| EXPAREL | $147.82M | $143.27M | $155.78M | $139.90M | $142.92M | $136.53M | $147.68M | $132.00M | $136.85M | $132.43M | $143.92M | $128.67M | 76.8% | +3.4% |
| ZILRETTA | $32.65M | $26.77M | $32.98M | $28.98M | $31.33M | $23.34M | $33.12M | $28.42M | $30.71M | $25.84M | $28.71M | $28.80M | 17.0% | +4.2% |
| iovera | $6.81M | $6.18M | $7.00M | $6.47M | $5.59M | $5.12M | $6.45M | $5.66M | $5.67M | $5.03M | $6.04M | $5.26M | 3.5% | +21.8% |
| Bupivacaine liposome injectable suspension | $3.22M | $1.16M | $1.11M | $2.69M | $508.00K | $2.60M | $0 | $1.64M | $3.15M | $2.53M | $1.10M | $858.00K | 1.7% | +533.1% |
| Royalty revenue | $1.91M | $0 | $0 | $1.48M | $752.00K | $1.33M | $0 | $851.00K | $1.64M | $1.29M | $1.48M | $343.00K | 1.0% | +153.5% |
| EXPAREL | – | – | – | – | – | – | – | – | – | – | – | $128.67M | – | – |
By region
From the segment and revenue-disaggregation notes of Pacira BioSciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.